Schering Temodal Tumor Response Supports Astrocytoma, Not Glioblastoma
Executive Summary
Schering-Plough's Temodal (temozolomide) should be granted accelerated approval based on tumor response rates for treatment of anaplastic astrocytoma in patients who relapse following treatment with a nitrosourea (BCNU or CCNU) and procarbazine, the Oncologic Drugs Advisory Committee recommended Jan. 12.
You may also be interested in...
Schering Temodar Confirmatory Trial To Test Combination Use With BCNU
A Phase IV confirmatory trial will explore the combination of Schering's Temodar (temozolomide) with BCNU in addition to comparing the oncologic agent to BCNU head to head in anaplastic astrocytoma. The trial is required following the accelerated approval of temozolomide Aug. 11.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011